Physician profile
Mark E Lamielle
NPI 1609877752
$691.52
in general payments reported to CMS, 2019-2025
13 companies · $62.48 in 2025
The $62.48 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $92.34 · 2021: $67.88 · 2022: $65.53 · 2023: $96.13 · 2024: $98.93 · 2025: $62.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $322.38 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $108.00 | 2019-2020 | |
| Pfizer INC. | $69.30 | 2019-2020 | |
| Abbvie INC. | $34.97 | 2019 | |
| Amgen INC. | $28.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.31 | 2022 | |
| Dynavax Technologies Corporation | $18.97 | 2021 | |
| Merck Sharp & Dohme LLC | $13.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.37 | 2020 | |
| Daiichi Sankyo INC. | $12.05 | 2019 | |
| Lilly USA, LLC | $11.81 | 2020 | |
| Allergan, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lamielle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.